Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

APRI 1.41 -0.02 (-1.38%)
price chart
RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up
Apricus Biosciences Inc. (NASDAQ:APRI) is trading up by around 15.58% as of 11:14 AM EST. The buying spree on the stock followed the announcement from the United States Patent and Trademark Office (USPTO) on Tuesday, awarding the patent to ...
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)  GlobeNewswire (press release)
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
Apricus first launched Vitaros commercially six months ago in the UK, and followed up with Germany, Sweden, and Belgium. There has been some positive feedback from user experiences, followed up with some areas that could be improved.
Related articles »  
Apricus Biosciences Announces Corporate Update and Third Quarter 2014 ...
SAN DIEGO, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the Company's third quarter financial results will ...
Related articles »  
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences Announces the Appointment of Catherine Bovenizer as ...
Apricus Biosciences, Inc. APRI, +15.57% a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Catherine Bovenizer as the Company's Vice President of Finance, Chief Accounting ...
Apricus Biosciences Inc Analyst Rating Update  Stafford Daily
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Brian T. Dorsey as the Company's ...
Related articles »  
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
SAN DIEGO, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Barbara Troupin, M.D.
Apricus Bio appoints Barbara Troupin as CMO  San Diego Source (subscription)
Related articles »  
Friday Stocks to Watch: Apricus Biosciences Inc , Glacier Bancorp Inc ...
Apricus Biosciences Inc (APRI) gained 0.1 points to close 7.5188% higher. The session began with the first transaction at 1.4 and the price swung wildly to hit a low of 1.33 and a high of 1.505.
Will Apricus Biosciences (APRI) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Apricus Biosciences Inc (APRI - Snapshot Report). The stock has moved higher by 13.6% in the past month, while it is also above its 20 Day SMA too.
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical ...
SAN DIEGO, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the first patient has been enrolled in the Phase ...
Related articles »